Based on the analysis of Passage Bio's profitability, liquidity, and operating efficiency, Passage Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Passage Bio's Total Current Liabilities is most likely to increase significantly in the upcoming years. The Passage Bio's current Total Stockholder Equity is estimated to increase to about 201.3 M, while Property Plant And Equipment Net is projected to decrease to roughly 18.7 M. Key indicators impacting Passage Bio's financial strength include:
The essential information of the day-to-day investment outlook for Passage Bio includes many different criteria found on its balance sheet. An individual investor should monitor Passage Bio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Passage Bio.
Net Income
(107.17 Million)
Passage
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Sale Purchase Of Stock
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Capital Stock
Net Working Capital
Common Stock
Property Plant Equipment
Common Stock Total Equity
Accumulated Other Comprehensive Income
Net Receivables
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Cost Of Revenue
Non Recurring
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Passage Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Passage Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Passage Bio's assets may result in an increase in income on the income statement.
Passage Bio competes with Black Diamond, Revolution Medicines, Stoke Therapeutics, and Cabaletta Bio. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Passage Bio's current stock value. Our valuation model uses many indicators to compare Passage Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Passage Bio competition to find correlations between indicators driving Passage Bio's intrinsic value. More Info.
Passage Bio is regarded fifth in return on equity category among its peers. It also is regarded fifth in return on asset category among its peers . At this time, Passage Bio's Return On Equity is most likely to slightly decrease in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Passage Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Passage Bio Systematic Risk
Passage Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Passage Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Passage Bio correlated with the market. If Beta is less than 0 Passage Bio generally moves in the opposite direction as compared to the market. If Passage Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Passage Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Passage Bio is generally in the same direction as the market. If Beta > 1 Passage Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Passage Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Passage Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Passage Bio growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Passage Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Passage Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Passage Bio based on widely used predictive technical indicators. In general, we focus on analyzing Passage Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Passage Bio's daily price indicators and compare them against related drivers.
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.